Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
about
Effective immunosuppressive management with belatacept and eculizumab in post-transplant aHUS due to a homozygous deletion of CFHR1/CFHR3 and the presence of CFH antibodies.Complement-mediated renal diseases after kidney transplantation - current diagnostic and therapeutic options in and recurrent diseasesThrombotic microangiopathy after renal transplantation: Current insights in and recurrent disease
P2860
Eculizumab and Belatacept for De Novo Atypical Hemolytic Uremic Syndrome Associated With CFHR3-CFHR1 Deletion in a Kidney Transplant Recipient: A Case Report.
description
2017 nî lūn-bûn
@nan
2017 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Eculizumab and Belatacept for ...... lant Recipient: A Case Report.
@ast
Eculizumab and Belatacept for ...... lant Recipient: A Case Report.
@en
type
label
Eculizumab and Belatacept for ...... lant Recipient: A Case Report.
@ast
Eculizumab and Belatacept for ...... lant Recipient: A Case Report.
@en
prefLabel
Eculizumab and Belatacept for ...... lant Recipient: A Case Report.
@ast
Eculizumab and Belatacept for ...... lant Recipient: A Case Report.
@en
P2093
P1476
Eculizumab and Belatacept for ...... lant Recipient: A Case Report.
@en
P2093
B G Abu Jawdeh
E S Woodle
G Mogilishetty
R R Alloway
P304
P356
10.1016/J.TRANSPROCEED.2016.11.008
P407
P577
2017-01-01T00:00:00Z